Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000664975 | SCV003441222 | likely pathogenic | Phenylketonuria | 2022-01-16 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Cys217 amino acid residue in PAH. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8807319, 32668217). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PAH protein function. ClinVar contains an entry for this variant (Variation ID: 102770). This missense change has been observed in individual(s) with clinical features of hyperphenylalaninemia (PMID: 18798839, 29499199, 32668217). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 217 of the PAH protein (p.Cys217Arg). |
Baylor Genetics | RCV000664975 | SCV005053841 | likely pathogenic | Phenylketonuria | 2023-12-24 | criteria provided, single submitter | clinical testing | |
De |
RCV000089020 | SCV000119625 | not provided | not provided | no assertion provided | not provided | ||
Counsyl | RCV000664975 | SCV000789021 | uncertain significance | Phenylketonuria | 2016-12-27 | flagged submission | clinical testing |